# Parabilis Medicines Parabilis Medicines is an Asset Manager based in United States. ## Overview - **Organization type:** Asset Manager - **Headquarters:** United States - **Region:** North America - **Assets under management:** Undisclosed - **Website:** parabilismed.com ## Regulatory record - **Reports private funds:** No ## About Parabilis Medicines was founded to recast how preclinical assets are sourced and validated. Rather than screening external companies or licensing university discoveries, the firm builds internal programs from computationally generated hypotheses — a model that borrows from tech platform economics and applies them to drug R&D. The founding team has roots in machine-learning labs and therapeutic-area leadership at biopharma companies, though operational details remain closely held. The firm funnels its platform — described in public records as integrating deep learning on multimodal biological data — toward concrete drug programs. Its disclosed pipeline targets oncology, immunology, and metabolic disease, spanning small-molecule and biologic modalities. Program initiation relies on proprietary predictive models that rank novel target-compound pairings, a workflow the firm's communications frame as capital-efficient by design. Parabilis advances these candidates through IND-enabling studies internally, occasionally partnering with contract research organizations for execution but retaining full program ownership. Scale indicators are scarce. Operations appear concentrated in a single US hub, with public records pointing to a lean team of computational scientists, translational biologists, and drug developers. The firm has not disclosed participation in investor syndicates, family-office networks, or philanthropic vehicles. As of mid-2026, no recent fund closings, key hires, or pipeline milestones have been surfaced through official channels. Parabilis marks a structural departure from both the venture-funded biotech startup and the diversified asset manager. Without a disclosed fund structure, it operates closer to a proprietary biopharma R&D unit — one that relies on algorithmic target generation rather than academic collaborations or in-licensing. ## Sectors - AI/ML - Digital Health - Healthcare Services ## Questions ### What sets Parabilis Medicines apart from a typical biotech venture firm? Parabilis does not invest in external biotech startups — it builds and wholly owns its drug programs. The firm uses proprietary machine-learning models to surface therapeutic targets and then advances those assets internally, operating more like a tech-bio R&D company than a fund deploying capital into third-party ventures. Public records indicate no outside portfolio companies or fund commitments. ### Which therapeutic areas does Parabilis target? Based on the firm's public communications, its pipeline covers oncology, immunology, and metabolic disease. The platform is designed to work across both small-molecule and biologic modalities, though the exact number of programs and their clinical stages have not been publicly detailed. ### How does Parabilis use artificial intelligence in drug development? Parabilis applies deep learning to multimodal biological datasets to predict novel target-compound pairings. The computational engine ranks these candidates before any wet-lab work begins, aiming to reduce the attrition rate that plagues traditional target identification. This upfront algorithmic triage is the core of the firm's operating model. ## Related profiles - [Grayscale Decentraland Trust (MANA)](https://altss.com/profile/grayscale-decentraland-trust-mana) - [Melrose Industries](https://altss.com/profile/melrose-industries-plcadr) --- Last updated: 2026-08-11T02:43:31.692Z Canonical page: https://altss.com/profile/parabilis-medicines-inc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology